

5367.230-US  
November 23, 2004

Application Number 10/730,215  
Page 2 of 5

## AMENDMENTS TO THE CLAIMS

The following Listing of Claims replaces all prior versions, and listings, of claims in this Application.

### LISTING OF CLAIMS

1-3 (cancelled)

4. (currently amended) A method of promoting the treatment of intestinal cancer damage therapy in a patient comprising administering to the patient an effective amount of a pharmaceutically acceptable composition comprising (a) a non-naturally occurring polypeptide having an amino acid sequence according to the formula ~~X1-H-X2-D-G-S-F-S-D-E-M-N-T-X3-L-D-X4-L-A-X5-X6-D-F-I-N-W-L-X7-X8-T-K-I-T-D-X9-~~ His Xaa<sup>2</sup> D Asp Gly Ser Phe Ser Asp Glu Met Asn Thr Xaa<sup>3</sup> Leu Asp Xaa<sup>4</sup> Leu Ala Xaa<sup>5</sup> Xaa<sup>6</sup> D Asp Phe Ile Asn Trp Leu Xaa<sup>7</sup> Xaa<sup>8</sup> Thr Lys Ile Thr Asp Xaa<sup>9</sup> Xaa<sup>10</sup> (SEQ ID NO:1), wherein Xaa<sup>2</sup> is Ala or Gly; Xaa<sup>3</sup> is Ile or Val; Xaa<sup>4</sup> is Asn, Ser or His; Xaa<sup>5</sup> is Ala or Thr; Xaa<sup>6</sup> is Arg or Lys; Xaa<sup>7</sup> is Ile or Leu; Xaa<sup>8</sup> is Gln or His; Xaa<sup>9</sup> is OH, Lys, or Arg, and Xaa<sup>10</sup> is Lys, Arg, or is missing and optionally further including an N-terminal positioned sequence selected from Asp Phe Pro Glu Glu Val Ala Ile Val Glu Glu Leu Gly Arg Arg (SEQ ID NO:2), Asp Phe Pro Glu Glu Val Thr Ile Val Glu Glu Leu Gly Arg Arg (SEQ ID NO:3), Asp Phe Pro Glu Glu Val Asn Ile Val Glu Glu Leu Arg Arg Arg (SEQ ID NO:4), or a fragment of any of SEQ ID NOS:2-4, and

(b) a pharmaceutically acceptable combination of (i) an isotonic agent, (ii) a buffer, and (iii) a preservative, a surfactant, or a combination of a surfactant and a preservative, wherein (I) ~~X1 is NH<sub>2</sub>, DFPEEVAIVEELGRR (SEQ ID NO:2), DFPEEVTIVEELGRR (SEQ ID NO:3), DFPEEVNIVEELRRR (SEQ ID NO:4), or a fragment of any of SEQ ID NOS:2-4; X2 is Ala or Gly; X3 is Ile or Val; X4 is Asn, Ser, or His; X5 is Ala or Thr; X6 is Arg or Lys; X7 is Ile or Leu; X8 is Gln or His; and X9 is OH, Lys, Arg, Arg-Lys, Lys-Arg, Arg-Arg, or Lys-Lys and (II) the solubility~~

5367.230-US  
November 23, 2004

Application Number 10/730,215  
Page 3 of 5

of the peptide, stability of the peptide, or both is significantly greater than the solubility and/or stability of the peptide without the combination to the patient.

5. (currently amended) The method of claim 4, wherein Xaa<sup>2</sup> represents Gly.

6-9 (cancelled)

10. (currently amended) A method of promoting the treatment of ~~small bowel syndrome, Crohn's disease, ileitis, intestinal inflammation, gastric ulceration, duodenal ulceration, inflammatory bowel disease, or intestinal cancer damage therapy~~ in a patient comprising administering an effective amount of ~~the peptide of claim 6~~ a non-naturally occurring polypeptide having an amino acid sequence according to the formula His Xaa<sup>2</sup>  $\Theta$  Asp Gly Ser Phe Ser Asp Glu Met Asn Thr Xaa<sup>3</sup> Leu Asp Xaa<sup>4</sup> Leu Ala Xaa<sup>5</sup> Xaa<sup>6</sup>  $\Theta$  Asp Phe Ile Asn Trp Leu Xaa<sup>7</sup> Xaa<sup>8</sup> Thr Lys Ile Thr Asp Xaa<sup>9</sup> Xaa<sup>10</sup> (SEQ ID NO:1), wherein Xaa<sup>2</sup> is Ala or Gly; Xaa<sup>3</sup> is Ile or Val; Xaa<sup>4</sup> is Asn, Ser or His; Xaa<sup>5</sup> is Ala or Thr; Xaa<sup>6</sup> is Arg or Lys; Xaa<sup>7</sup> is Ile or Leu; Xaa<sup>8</sup> is Gln or His; Xaa<sup>9</sup> is OH, Lys, or Arg, and Xaa<sup>10</sup> is Lys, Arg, or is missing and optionally further including an N-terminal positioned sequence selected from Asp Phe Pro Glu Glu Val Ala Ile Val Glu Glu Leu Gly Arg Arg (SEQ ID NO:2), Asp Phe Pro Glu Glu Val Thr Ile Val Glu Glu Leu Gly Arg Arg (SEQ ID NO:3), Asp Phe Pro Glu Glu Val Asn Ile Val Glu Glu Leu Arg Arg Arg (SEQ ID NO:4), or a fragment of any of SEQ ID NOS:2-4 ~~X1 H X2 D G S F S D E M N T X3 L D X4 L A X5 X6 D F I N W L X7 X8 T K I T D X9~~ (SEQ ID NO: 1), wherein ~~(i) X1 is NH<sub>2</sub>, DFPEEVAIVEELGRR (SEQ ID NO:2), DFPEEVIVEELGRR (SEQ ID NO:3), DFPEEVNIVEELRRR (SEQ ID NO:4), or a fragment of any of SEQ ID NOS:2-4; X2 is Ala or Gly; X3 is Ile or Val; X4 is Asn, Ser, or His; X5 is Ala or Thr; X6 is Arg or Lys; X7 is Ile or Leu; X8 is Gln or His; and X9 is OH, Lys, Arg, Arg-Lys, Lys Arg, Arg Arg, or Lys-Lys to the patient.~~

5367.230-US  
November 23, 2004

Application Number 10/730,215  
Page 4 of 5

---

11. (currently amended) The method of claim 10, wherein Xaa<sup>2</sup>  
X<sub>2</sub> represents Gly.

12. (previously presented) The method of claim 10, wherein  
the composition comprises a preservative.

13. (previously presented) The method of claim 12, wherein  
the composition comprises a surfactant.

14. (previously presented) The method of claim 4, wherein  
the method comprises reconstituting a lyophilized composition comprising  
the non-naturally occurring polypeptide and preparing the  
pharmaceutically acceptable composition prior to administering the  
pharmaceutically acceptable composition to the patient.

15. (previously presented) The method of claim 10, wherein  
the method comprises reconstituting a lyophilized composition comprising  
the non-naturally occurring polypeptide prior to administering the  
polypeptide to the patient.